Subtherapeutic Doses of SSRI Antidepressants Demonstrate Considerable Serotonin Transporter Occupancy: Implications for Tapering SSRIs

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2018 Aug 12

PMID 30097698

Citations 7

Authors

Bryan B Shapiro

Affiliations

Soon will be listed here.

Citing Articles

Machine Learning-Based Prediction of Escitalopram and Sertraline Side Effects With Pharmacokinetic Data in Children and Adolescents.

Poweleit E, Vaughn S, Desta Z, Dexheimer J, Strawn J, Ramsey L Clin Pharmacol Ther. 2024; 115(4):860-870.

PMID: 38297828 PMC: 11046530. DOI: 10.1002/cpt.3184.

Adverse Effects of Antidepressant Medications and their Management in Children and Adolescents.

Strawn J, Mills J, Poweleit E, Ramsey L, Croarkin P Pharmacotherapy. 2023; 43(7):675-690.

PMID: 36651686 PMC: 10378577. DOI: 10.1002/phar.2767.

Short-course antidepressant therapy reduces discontinuation syndrome while maintaining treatment efficacy in patients with refractory functional dyspepsia: A randomized controlled trial.

Wang Q, Cheng L, Wu B, Xu P, Qiu H, Wang B Front Psychiatry. 2022; 13:1063722.

PMID: 36569610 PMC: 9772443. DOI: 10.3389/fpsyt.2022.1063722.

Designing Flexible Longitudinal Regimens: Supporting Clinician Planning for Discontinuation of Psychiatric Drugs.

Jo E, Ryu M, Kenderova G, So S, Shapiro B, Papoutsaki A Proc SIGCHI Conf Hum Factor Comput Syst. 2022; 2022.

PMID: 35789138 PMC: 9247721. DOI: 10.1145/3491102.3502206.

Serotonin Reuptake Inhibitors and the Gut Microbiome: Significance of the Gut Microbiome in Relation to Mechanism of Action, Treatment Response, Side Effects, and Tachyphylaxis.

Sjostedt P, Enander J, Isung J Front Psychiatry. 2021; 12:682868.

PMID: 34122195 PMC: 8187765. DOI: 10.3389/fpsyt.2021.682868.

References

Kotzalidis G, De Pisa E, Patrizi B, Savoja V, Ruberto G, Girardi P . Similar discontinuation symptoms for withdrawal from medium-dose paroxetine and venlafaxine after nine years in the same patient. J Psychopharmacol. 2008; 22(5):581-4. DOI: 10.1177/0269881107081562. View

Keuthen N, Cyr P, Ricciardi J, Minichiello W, Buttolph M, Jenike M . Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmacol. 1994; 14(3):206-7. DOI: 10.1097/00004714-199406000-00010. View

Sir A, Dsouza R, Uguz S, George T, Vahip S, Hopwood M . Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry. 2005; 66(10):1312-20. DOI: 10.4088/jcp.v66n1015. View

Warner C, Bobo W, Warner C, Reid S, Rachal J . Antidepressant discontinuation syndrome. Am Fam Physician. 2006; 74(3):449-56. View

Tint A, Haddad P, Anderson I . The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol. 2008; 22(3):330-2. DOI: 10.1177/0269881107081550. View

Meyer J, Wilson A, Sagrati S, Hussey D, Carella A, Potter W . Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004; 161(5):826-35. DOI: 10.1176/appi.ajp.161.5.826. View

Murata Y, Kobayashi D, Imuta N, Haraguchi K, Ieiri I, Nishimura R . Effects of the serotonin 1A, 2A, 2C, 3A, and 3B and serotonin transporter gene polymorphisms on the occurrence of paroxetine discontinuation syndrome. J Clin Psychopharmacol. 2010; 30(1):11-7. DOI: 10.1097/JCP.0b013e3181c8ae80. View

Arakawa R, Tateno A, Kim W, Sakayori T, Ogawa K, Okubo Y . Time-course of serotonin transporter occupancy by single dose of three SSRIs in human brain: A positron emission tomography study with [(11)C]DASB. Psychiatry Res Neuroimaging. 2016; 251:1-6. DOI: 10.1016/j.pscychresns.2016.03.006. View

Rosenbaum J, Fava M, Hoog S, Ascroft R, Krebs W . Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998; 44(2):77-87. DOI: 10.1016/s0006-3223(98)00126-7. View

10.

Freeman M, White W, Iranikhah M . Tablet splitting: a review of weight and content uniformity. Consult Pharm. 2012; 27(5):341-52. DOI: 10.4140/TCP.n.2012.341. View

11.

Fava G, Bernardi M, Tomba E, Rafanelli C . Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol. 2007; 10(6):835-8. DOI: 10.1017/S1461145706007462. View

12.

Baldessarini R, Tondo L, Ghiani C, Lepri B . Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry. 2010; 167(8):934-41. DOI: 10.1176/appi.ajp.2010.09060880. View

13.

Chouinard G, Chouinard V . New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal. Psychother Psychosom. 2015; 84(2):63-71. DOI: 10.1159/000371865. View

14.

Fava G, Offidani E . The mechanisms of tolerance in antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 35(7):1593-602. DOI: 10.1016/j.pnpbp.2010.07.026. View